Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Angiotensin-(3-4) (Ang-(3-4) or Val-Tyr) is the shortest peptide derived from angiotensin II, consisting of the dipeptide valine and tyrosine. It is formed through successive hydrolysis of longer angiotensins in both plasma and kidney, making it a component of the systemic and organ-based renin–angiotensin system. Angiotensin-(3-4) acts as a potent antihypertensive agent in humans and rats, primarily by inhibiting fluid reabsorption in renal proximal tubule cells, leading to increased urinary sodium excretion. Mechanistically, it counteracts effects mediated by the angiotensin II type 1 receptor (AT1R) by acting as an allosteric enhancer at the angiotensin II type 2 receptor (AT2R). This action modulates ATP-dependent Ca²⁺ and Na⁺ transporters via a cAMP-dependent protein kinase pathway. It is orally bioavailable due to its resistance to hydrolysis and high intestinal permeability[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on angiotensin-(3-4).